Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1984 1
1985 5
1986 5
1987 9
1988 4
1989 1
1990 3
1991 2
1992 5
1993 6
1994 9
1995 6
1996 13
1997 20
1998 14
1999 16
2000 27
2001 31
2002 46
2003 38
2004 65
2005 67
2006 81
2007 100
2008 96
2009 110
2010 110
2011 112
2012 108
2013 97
2014 95
2015 101
2016 81
2017 57
2018 69
2019 67
2020 61
2021 64
2022 51
2023 45
2024 33
2025 46
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,704 results

Results by year

Filters applied: . Clear all
Page 1
Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial.
Hoge EA, Bui E, Mete M, Dutton MA, Baker AW, Simon NM. Hoge EA, et al. JAMA Psychiatry. 2023 Jan 1;80(1):13-21. doi: 10.1001/jamapsychiatry.2022.3679. JAMA Psychiatry. 2023. PMID: 36350591 Free PMC article. Clinical Trial.
OBJECTIVE: To determine whether MBSR is noninferior to escitalopram, a commonly used first-line psychopharmacological treatment for anxiety disorders. ...Secondary intent-to-treat analyses using imputed data also showed the noninferiority of MBSR compared with escitalop …
OBJECTIVE: To determine whether MBSR is noninferior to escitalopram, a commonly used first-line psychopharmacological treatment for a …
Trial of Psilocybin versus Escitalopram for Depression.
Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ. Carhart-Harris R, et al. N Engl J Med. 2021 Apr 15;384(15):1402-1411. doi: 10.1056/NEJMoa2032994. N Engl J Med. 2021. PMID: 33852780 Clinical Trial.
METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were as …
METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive …
Increased global integration in the brain after psilocybin therapy for depression.
Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, Roseman L, Nutt D, Carhart-Harris R. Daws RE, et al. Nat Med. 2022 Apr;28(4):844-851. doi: 10.1038/s41591-022-01744-z. Epub 2022 Apr 11. Nat Med. 2022. PMID: 35411074 Clinical Trial.
The second trial was a double-blind phase II randomized controlled trial comparing psilocybin therapy with escitalopram. Patients with major depressive disorder received either 2 25 mg oral psilocybin, 3 weeks apart, plus 6 weeks of daily placebo ('psilocybin arm') or 2 …
The second trial was a double-blind phase II randomized controlled trial comparing psilocybin therapy with escitalopram. Patients wit …
Effect of Exercise, Escitalopram, or Placebo on Anxiety in Patients With Coronary Heart Disease: The Understanding the Benefits of Exercise and Escitalopram in Anxious Patients With Coronary Heart Disease (UNWIND) Randomized Clinical Trial.
Blumenthal JA, Smith PJ, Jiang W, Hinderliter A, Watkins LL, Hoffman BM, Kraus WE, Liao L, Davidson J, Sherwood A. Blumenthal JA, et al. JAMA Psychiatry. 2021 Nov 1;78(11):1270-1278. doi: 10.1001/jamapsychiatry.2021.2236. JAMA Psychiatry. 2021. PMID: 34406354 Free PMC article. Clinical Trial.
Participants randomized to the exercise group and escitalopram group reported greater reductions in HADS-A (exercise, -4.0; 95% CI, -4.7 to -3.2; escitalopram, -5.7; 95% CI, -6.4 to -5.0) compared with those randomized to placebo (-3.5; 95% CI, -4.5 to -2.4; P = .03 …
Participants randomized to the exercise group and escitalopram group reported greater reductions in HADS-A (exercise, -4.0; 95% CI, - …
Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study.
Strawn JR, Mills JA, Schroeder H, Mossman SA, Varney ST, Ramsey LB, Poweleit EA, Desta Z, Cecil K, DelBello MP. Strawn JR, et al. J Clin Psychiatry. 2020 Aug 25;81(5):20m13396. doi: 10.4088/JCP.20m13396. J Clin Psychiatry. 2020. PMID: 32857933 Free PMC article. Clinical Trial.
Vital signs, corrected QT interval, and adverse events were similar in patients who received escitalopram and placebo. CONCLUSIONS: Escitalopram reduces anxiety symptoms, and pharmacogenetics variables influence the trajectory and magnitude of improvement. Variation …
Vital signs, corrected QT interval, and adverse events were similar in patients who received escitalopram and placebo. CONCLUSIONS: …
The safety and efficacy of escitalopram and sertraline in post-stroke depression: a randomized controlled trial.
Yan N, Hu S. Yan N, et al. BMC Psychiatry. 2024 May 15;24(1):365. doi: 10.1186/s12888-024-05833-w. BMC Psychiatry. 2024. PMID: 38750479 Free PMC article. Clinical Trial.
OBJECTIVES: This study aims to evaluate the safety and efficacy of escitalopram and sertraline in post-stroke depression (PSD) patients, to provide more reliable therapeutics for cardiovascular and psychiatric clinical practice. ...In addition, escitalopram was more …
OBJECTIVES: This study aims to evaluate the safety and efficacy of escitalopram and sertraline in post-stroke depression (PSD) patien …
Generalizability of Treatment Outcome Prediction Across Antidepressant Treatment Trials in Depression.
Zhukovsky P, Trivedi MH, Weissman M, Parsey R, Kennedy S, Pizzagalli DA. Zhukovsky P, et al. JAMA Netw Open. 2025 Mar 3;8(3):e251310. doi: 10.1001/jamanetworkopen.2025.1310. JAMA Netw Open. 2025. PMID: 40111362 Free PMC article. Clinical Trial.
OBJECTIVE: To assess whether neuroimaging and clinical features predict response to sertraline and escitalopram in patients with major depressive disorder (MDD) across 2 multisite studies using machine learning and to predict change in depression severity in 2 independent …
OBJECTIVE: To assess whether neuroimaging and clinical features predict response to sertraline and escitalopram in patients with majo …
Simvastatin as Add-On Treatment to Escitalopram in Patients With Major Depression and Obesity: A Randomized Clinical Trial.
Otte C, Chae WR, Dogan DY, Piber D, Roepke S, Cho AB, Trumm S, Kaczmarczyk M, Brasanac J, Wingenfeld K, Koglin S, Wieditz J, Junghanns K, Lucht M, Prvulovic D, Krüger THC, Terock J, Haaf M, Hofmann T, Mauche N, Klein JP, Grabe HJ, Reif A, Kahl KG, Janowitz D, Leicht G, Hinkelmann K, Strauß M, Friede T, Gold SM. Otte C, et al. JAMA Psychiatry. 2025 Aug 1;82(8):759-767. doi: 10.1001/jamapsychiatry.2025.0801. JAMA Psychiatry. 2025. PMID: 40465256 Free PMC article. Clinical Trial.
OBJECTIVE: To examine whether simvastatin added to escitalopram is efficacious in improving depressive symptoms compared with add-on placebo. ...INTERVENTIONS: Simvastatin (40 mg per day) or placebo as add-on to escitalopram (10 mg for the first 2 weeks, then increa …
OBJECTIVE: To examine whether simvastatin added to escitalopram is efficacious in improving depressive symptoms compared with add-on …
A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder.
Strawn JR, Moldauer L, Hahn RD, Wise A, Bertzos K, Eisenberg B, Greenberg E, Liu C, Gopalkrishnan M, McVoy M, Knutson JA. Strawn JR, et al. J Child Adolesc Psychopharmacol. 2023 Apr;33(3):91-100. doi: 10.1089/cap.2023.0004. J Child Adolesc Psychopharmacol. 2023. PMID: 37074330 Free article. Clinical Trial.
Vital signs, weight, laboratory, and electrocardiographic results were consistent with previous pediatric studies of escitalopram. Conclusions: Escitalopram reduced anxiety symptoms and was well tolerated in pediatric patients with GAD. These findings confirm earlie …
Vital signs, weight, laboratory, and electrocardiographic results were consistent with previous pediatric studies of escitalopram. Co …
Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.
Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, Duthaler U, Varghese N, Eckert A, Grünblatt E, Liechti ME. Becker AM, et al. Clin Pharmacol Ther. 2022 Apr;111(4):886-895. doi: 10.1002/cpt.2487. Epub 2021 Nov 22. Clin Pharmacol Ther. 2022. PMID: 34743319 Free PMC article. Clinical Trial.
Escitalopram did not alter the pharmacokinetics of psilocin. The half-life of psychoactive free (unconjugated) psilocin was 1.8 hours (range 1.1-2.2 hours), consistent with the short duration of action of psilocybin. Escitalopram did not alter HTR2A or SCL6A4 gene e …
Escitalopram did not alter the pharmacokinetics of psilocin. The half-life of psychoactive free (unconjugated) psilocin was 1.8 hours …
1,704 results